Mesoblast Limited
MESO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $7 | $7 | $2 | $2 |
| % Growth | 0% | 344.9% | 0% | – |
| Cost of Goods Sold | $23 | $23 | $3 | $3 |
| Gross Profit | -$16 | -$16 | -$2 | -$2 |
| % Margin | -231.1% | -231.1% | -107.8% | -107.8% |
| R&D Expenses | $7 | $7 | $10 | $10 |
| G&A Expenses | $9 | $9 | $9 | $9 |
| SG&A Expenses | $11 | $11 | $9 | $9 |
| Sales & Mktg Exp. | $2 | $2 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $18 | $18 | $19 | $19 |
| Operating Income | -$34 | -$34 | -$21 | -$21 |
| % Margin | -489.5% | -489.5% | -1,306.7% | -1,306.7% |
| Other Income/Exp. Net | $7 | $7 | -$3 | -$3 |
| Pre-Tax Income | -$27 | -$27 | -$24 | -$24 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27 | -$27 | -$24 | -$24 |
| % Margin | -386% | -386% | -1,518.8% | -1,518.8% |
| EPS | -0.21 | -0.21 | -0.21 | -0.21 |
| % Growth | 0% | 0% | 0% | – |
| EPS Diluted | -0.21 | -0.21 | -0.21 | -0.21 |
| Weighted Avg Shares Out | 127 | 127 | 114 | 114 |
| Weighted Avg Shares Out Dil | 127 | 127 | 114 | 114 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $5 | $5 |
| Depreciation & Amortization | $2 | $2 | $1 | $1 |
| EBITDA | -$20 | -$20 | -$9 | -$9 |
| % Margin | -279.7% | -279.7% | -599.1% | -599.1% |